Aging considerations of cytokines (IL-18, IL-36α, IL-37, and IL-38) associated with rheumatoid arthritis

References

• Shi G, Liao X, Lin Z, et al. Estimation of the global prevalence, incidence, years lived with disability of rheumatoid arthritis in 2019 and forecasted incidence in 2040: results from the global Burden of disease Study 2019. Clin Rheumatol. 2023;42:2297–2309. doi: 10.1007/s10067-023-06628-2
   PubMed Web of Science ®Google Scholar
• Romão VC, Fonseca JE. Etiology and risk factors for rheumatoid arthritis: a state-of-the-art review. Front Med. 2021;8:689698. doi: 10.3389/fmed.2021.689698
   PubMed Web of Science ®Google Scholar
• Novella-Navarro M, Plasencia-Rodríguez C, Nuño L, et al. Risk factors for developing rheumatoid arthritis in patients with undifferentiated arthritis and inflammatory arthralgia. Front Med. 2021;8:668898. doi: 10.3389/fmed.2021.668898
   PubMed Web of Science ®Google Scholar
• Jang S, Kwon EJ, Lee JJ. Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int J Mol Sci. 2022;23:905. doi: 10.3390/ijms23020905
   PubMed Web of Science ®Google Scholar
• Alunno A, Carubbi F, Giacomelli R, et al. Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets. BMC Rheumatol. 2017;1:1–13. doi: 10.1186/s41927-017-0001-8
   PubMedGoogle Scholar
• Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2021;22:10922. doi: 10.3390/ijms222010922
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15:612–632. doi: 10.1038/s41584-019-0277-8
   PubMed Web of Science ®Google Scholar
• Migliorini P, Italiani P, Pratesi F, et al. The IL-1 family cytokines and receptors in autoimmune diseases. Autoimmun Rev. 2020;19:102617. doi: 10.1016/J.AUTREV.2020.102617
   PubMed Web of Science ®Google Scholar
• Vasilev G, Manolova I, Ivanova M, et al. The role of IL-18 in addition to Th17 cytokines in rheumatoid arthritis development and treatment in women. Sci Rep. 2021;11:1–9. doi: 10.1038/s41598-021-94841-x
   PubMed Web of Science ®Google Scholar
• Zhu J, Xie C, Qiu H, et al. Correlation between level of interleukin-37 and rheumatoid arthritis progression. Int J Gen Med. 2021;14:1905–1910. doi: 10.2147/IJGM.S309436
   PubMed Web of Science ®Google Scholar
• Wang C, Hu J, Shi J. Role of interleukin-36 in inflammatory joint diseases. J Zhejiang Univ (Med Sci). 2023;52(2):249–259. doi: 10.3724/zdxbyxb-2023-0034
   Google Scholar
• Xu WD, Su LC, He CS, et al. Plasma interleukin-38 in patients with rheumatoid arthritis. Int Immunopharmacol. 2018;65:1–7. doi: 10.1016/j.intimp.2018.09.028
   PubMed Web of Science ®Google Scholar
• Ihim SA, Abubakar SD, Zian Z, et al. Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment. Front Immunol. 2022;13:919973. doi: 10.3389/fimmu.2022.919973
   PubMed Web of Science ®Google Scholar
• Bassoy EY, Towne JE, Gabay C. Regulation and function of interleukin-36 cytokines. Immunol Rev. 2018;281:169–178. doi: 10.1111/imr.12610
   PubMed Web of Science ®Google Scholar
• Byrne J, Baker K, Houston A, et al. IL-36 cytokines in inflammatory and malignant diseases: not the new kid on the block anymore. Cell Mol Life Sci. 2021;78:6215–6227. doi: 10.1007/s00018-021-03909-4
   PubMed Web of Science ®Google Scholar
• Hamed RM, Mahmood MM, Ad’hiah AH. The abundance of interleukin-22, 37, and 38 post-vaccination and following COVID-19 recuperation. J Popul Ther Clin Pharmacol. 2023;30:505–514. doi: 10.47750/jptcp.2023.30.03.054
   Google Scholar
• Bai J, Li Y, Li M, et al. IL-37 as a potential biotherapeutics of inflammatory diseases. Curr Drug Targets. 2020;21:855–863. doi: 10.2174/1389450121666200429114926
   PubMed Web of Science ®Google Scholar
• Xie L, Huang Z, Li H, et al. IL-38: a new player in inflammatory autoimmune disorders. Biomolecules. 2019;9:345. doi: 10.3390/biom9080345
   PubMed Web of Science ®Google Scholar
• Diaz-Barreiro A, Huard A, Palmer G. Multifaceted roles of IL-38 in inflammation and cancer. Cytokine. 2022;151:155808. doi: 10.1016/j.cyto.2022.155808
   PubMed Web of Science ®Google Scholar
• Al-Tae FMD, Al-Harbi AA, Turki KW, et al. Interleukin -37 in rheumatoid arthritis: correlation with clinical severity and genetic polymorphisms in Mosul city, Iraq. Egypt J Immunol. 2023;30(2):162–173. doi: 10.55133/eji.300215
   PubMedGoogle Scholar
• Boutet MA, Bart G, Penhoat M, et al. Distinct expression of interleukin (IL)-36 α, β and γ , their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin Exp Immunol. 2016;184(2):159–173. doi: 10.1111/cei.12761
   PubMed Web of Science ®Google Scholar
• Koelman L, Pivovarova-Ramich O, Pfeiffer AFH, et al. Cytokines for evaluation of chronic inflammatory status in ageing research: reliability and phenotypic characterisation. Immun Ageing. 2019;16:1–12. doi: 10.1186/s12979-019-0151-1
   PubMed Web of Science ®Google Scholar
• Rea IM, Gibson DS, McGilligan V, et al. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:1. doi: 10.3389/fimmu.2018.00586
   PubMed Web of Science ®Google Scholar
• Nakajima A, Sakai R, Inoue E, et al. Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the national database of health insurance claims and specific health checkups of Japan. Int J Rheum Dis. 2020;23:1676–1684. doi: 10.1111/1756-185X.13974
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi: 10.1002/art.27584
   PubMed Web of Science ®Google Scholar
• Kumar BS, Suneetha P, Mohan A, et al. Comparison of disease activity score in 28 joints with ESR (DAS28), clinical disease activity index (CDAI), health assessment questionnaire disability index (HAQ-DI) & routine assessment of patient index data with 3 measures (RAPID3) for assessing disease. Indian J Med Res. 2017;146(8):57–62. doi: 10.4103/ijmr.IJMR_701_15
   Google Scholar
• Faul F, Erdfelder E, Lang AG, et al. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–191. doi: 10.3758/BF03193146
   PubMed Web of Science ®Google Scholar
• Dharmarajan TS. Physiology of aging. Geriatr. Gastroenterol. 2nd. Springer International Publishing; 2021 pp. 101–153. 10.1007/978-3-030-30192-7_5.
   Google Scholar
• Fuentes E, Fuentes M, Alarcón M, et al. Immune system dysfunction in the elderly. An Acad Bras Cienc. 2017;89:285–299. doi: 10.1590/0001-3765201720160487
   PubMed Web of Science ®Google Scholar
• Sadighi Akha AA. Aging and the immune system: an overview. J Immunol Methods. 2018;463:21–26. doi: 10.1016/j.jim.2018.08.005
   PubMed Web of Science ®Google Scholar
• Fulop T, Larbi A, Dupuis G, et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2018;8:328099. doi: 10.3389/fimmu.2017.01960
   Web of Science ®Google Scholar
• Santoro A, Bientinesi E, Monti D. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? Ageing Res Rev. 2021;71:101422. doi: 10.1016/j.arr.2021.101422
   PubMed Web of Science ®Google Scholar
• Li X, Li C, Zhang W, et al. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct Target Ther. 2023;8:1–29. doi: 10.1038/s41392-023-01502-8
   PubMed Web of Science ®Google Scholar
• Kaplanski G. Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev. 2018;281:138–153. doi: 10.1111/imr.12616
   PubMed Web of Science ®Google Scholar
• El-Awaisi J, Kavanagh DPJ, Rink MR, et al. Targeting IL-36 improves age-related coronary microcirculatory dysfunction and attenuates myocardial ischemia/reperfusion injury in mice. JCI Insight. 2022;7:e155236. doi: 10.1172/jci.insight.155236
   PubMed Web of Science ®Google Scholar
• Brunt VE, Ikoba AP, Ziemba BP, et al. Circulating interleukin-37 declines with aging in healthy humans: relations to healthspan indicators and IL37 gene SNPs. Geroscience. 2023;45:65–84. doi: 10.1007/s11357-022-00587-3
   PubMed Web of Science ®Google Scholar
• Gurău F, Silvestrini A, Matacchione G, et al. Plasma levels of interleukin-38 in healthy aging and in type 2 diabetes. Diabet Res Clin Pract. 2021;171:108585. doi: 10.1016/j.diabres.2020.108585
   PubMed Web of Science ®Google Scholar
• de Graaf DM, Teufel LU, Joosten LAB, et al. Interleukin-38 in health and disease. Cytokine. 2022;152:155824. doi: 10.1016/j.cyto.2022.155824
   PubMed Web of Science ®Google Scholar
• Bernardi S, Toffoli B, Tonon F, et al. Sex differences in proatherogenic cytokine levels. Int J Mol Sci. 2020;21:3861. doi: 10.3390/ijms21113861
   PubMed Web of Science ®Google Scholar
• Beenakker KGM, Westendorp RGJ, De Craen AJM, et al. Men have a stronger monocyte-derived cytokine production response upon stimulation with the gram-negative stimulus lipopolysaccharide than women: a pooled analysis including 15 study populations. J Innate Immun. 2020;12:142–153. doi: 10.1159/000499840
   PubMed Web of Science ®Google Scholar
• Taneja V. Sex hormones determine immune response. Front Immunol. 2018;9:1931. doi: 10.3389/fimmu.2018.01931
   PubMed Web of Science ®Google Scholar